← Russell 3000 cross-section

NUTX Nutex Health Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Technology

Scale

Market cap
$1.3bn
Revenue TTM
$847m
Net income TTM
$186m
Free cash flow
$274m
Composite score
88.1
Sector rank
#1881

Valuation

P / E
7.0
EV / EBITDA
2.9
EV / sales
1.3
FCF yield
20.94%
Earnings yield vs 10-yr
9.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
22.0%
EBITDA margin
46.5%
ROE
47.3%
ROIC
169.2%
Revenue growth
6.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

On average, greater than 99% of our net patient service revenue is paid by insurers, federal agencies and other non-patient third parties. Following are the results of operations for the periods presented (in thousands): (1) See reconciliation of net loss attributable to Nutex Health Inc. to Adjusted EBITDA under Non-GAAP Financial Measures. Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025 Net income attributable to Nutex Health Inc. was $65.8 million, or income of $9.38 per diluted share, for the three months ended June 30, 2026 compared to net loss attributable to Nutex Health Inc. of $17.7 million, or loss of $2.95 per share, for the s ame period 2025. …Nutex Health Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →